Full Text Journal Articles by
Author Reena Khanna

Advertisement

Find full text journal articles






Prospective Evaluation of Endoscopic and Histologic Indices in Pediatric Ulcerative Colitis Using Centralized Review.

Amanda Ricciuto, Nicholas Carman, Eric I Benchimol, Iram Siddiqui, Juan Putra, Reena Khanna, Anne M Griffiths, Thomas D Walters, Peter C Church,

<h4>Introduction</h4>We aimed to evaluate the reliability and validity of the Ulcerative Colitis (UC) Endoscopic Index of Severity (UCEIS) and Mayo Endoscopy Score (MES) and to validate the Robarts Histopathology Index (RHI) and Nancy Index (NI) in pediatric UC. We examined rectosigmoid and pancolonic versions of each instrument.<h4>Methods</h4>Single-center cross-sectional study of ... Read more >>

Am J Gastroenterol (The American journal of gastroenterology)
[2021, 116(10):2052-2059]

Cited: 0 times

View full text PDF listing >>



Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials.

Brian G Feagan, Reena Khanna, William J Sandborn, Séverine Vermeire, Walter Reinisch, Chinyu Su, Leonardo Salese, Haiyun Fan, Jerome Paulissen, Deborah A Woodworth, Wojciech Niezychowski, Bruce E Sands,

<h4>Background</h4>Endoscopy is routine in trials of ulcerative colitis therapies.<h4>Aim</h4>To investigate agreement between central and local Mayo endoscopic subscore (MES) reads in the OCTAVE programme METHODS: Flexible sigmoidoscopy was performed in tofacitinib induction (OCTAVE Induction 1&2, NCT01465763 and NCT01458951), maintenance (OCTAVE Sustain, NCT01458574) and open-label, long-term extension (OCTAVE Open, NCT01470612) studies. ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Clinical Guidelines for the Management of Inflammatory Bowel Disease.

Reena Khanna, Aze S Wilson, James C Gregor, Katherine L Prowse, Waggas Afif,

Gastroenterology (Gastroenterology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Ustekinumab Therapeutic Drug Monitoring-Impact on Clinical Practice: A Multicenter Cross-Sectional Observational Trial.

Waqqas Afif, Bernie Sattin, Dorota Dajnowiec, Reena Khanna, Cynthia H Seow, Martin Williamson, Kinda Karra, Yanli Wang, Long-Long Gao, Brian Bressler,

<h4>Background and aims</h4>The value of ustekinumab (UST) therapeutic drug monitoring (TDM) in clinical practice remains unclear. This study examined the impact of UST TDM on clinical decision making in patients with Crohn's disease (CD).<h4>Methods</h4>A total of 110 consecutive UST-treated CD patients were enrolled in this multicenter, single-arm cross-sectional study. During ... Read more >>

Dig Dis Sci (Digestive diseases and sciences)
[2021, :]

Cited: 0 times

View full text PDF listing >>



IgA-Mediated Warm Autoimmune Hemolytic Anemia as an Extraintestinal Manifestation in a Patient With Crohn Disease on Vedolizumab.

Matthew Cheah, Aze Wilson, Ziad Solh, Reena Khanna,

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2021, 27(9):e108-e109]

Cited: 0 times

View full text PDF listing >>



Correction to: Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.

Jurij Hanzel, Christopher Ma, Niels Vande Casteele, Reena Khanna, Vipul Jairath, Brian G Feagan,

Drugs (Drugs)
[2021, 81(14):1697]

Cited: 0 times

View full text PDF listing >>



Methods for handling missing segments in Crohn's disease clinical trials: analysis from the EXTEND trial.

Christopher Ma, Reena Khanna, Leonardo Guizzetti, Guangyong Zou, Brian G Feagan, Vipul Jairath,

Gut (Gut)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Early Combined Immunosuppression May Be More Effective for Reducing Complications in Isolated Colonic- vs Ileal-Dominant Crohn Disease.

Parambir S Dulai, Vipul Jairath, Guangyong Zou, Larry W Stitt, Reena Khanna, William J Sandborn, Brian G Feagan, Siddharth Singh,

<h4>Background</h4>We assessed whether differential efficacy of early combined immunosuppression (ECI) in comparison with conventional management (CM) is present in patients with Crohn disease (CD) according to disease location.<h4>Methods</h4>In this posthoc analysis of the Randomized Evaluation of an Algorithm for Crohn's Treatment trial, the effect of ECI vs CM modified by ... Read more >>

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2021, 27(5):639-646]

Cited: 0 times

View full text PDF listing >>



Ustekinumab for Ulcerative Colitis.

Reena Khanna, Waqqas Afif,

Gastroenterology (Gastroenterology)
[2021, 160(6):2184-2186]

Cited: 0 times

View full text PDF listing >>



Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.

Jurij Hanzel, Christopher Ma, Niels Vande Casteele, Reena Khanna, Vipul Jairath, Brian G Feagan,

In Crohn's disease and ulcerative colitis, inflammation is not limited to the digestive tract. Extraintestinal manifestations (EIMs), which affect up to 50% of patients, can substantially impair quality of life. EIMs may parallel luminal disease activity or have an independent course. They most commonly involve the musculoskeletal system (e.g., peripheral ... Read more >>

Drugs (Drugs)
[2021, 81(3):333-347]

Cited: 0 times

View full text PDF listing >>



Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials.

Reena Khanna, Christopher Ma, Vipul Jairath, Niels Vande Casteele, Guangyong Zou, Brian G Feagan,

In patients with Crohn's disease and ulcerative colitis, poor correlation between symptoms and active luminal inflammation has been well established. As a result, the field has moved towards the use of endoscopic assessment to evaluate inflammatory activity. Numerous endoscopic indices have been used for this purpose although none are completely ... Read more >>

Clin Gastroenterol Hepatol (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association)
[2020, :]

Cited: 0 times

View full text PDF listing >>



A More Severe Non-melanoma Skin Cancer Phenotype Is Seen in Patients with Inflammatory Bowel Disease on Tumor Necrosis Factor-α Antagonists.

Cassandra M Townsend, Reena Khanna, Aze Suzanne Wilson,

<h4>Background</h4>Limited data suggest that non-melanoma skin cancer (NMSC) risk is higher in patients with inflammatory bowel disease (IBD) particularly in those on a tumor necrosis factor-α antagonist (TNF antagonist). It remains unknown whether TNF antagonist exposure alters the clinical course of NMSC in patients with IBD or if this therapy ... Read more >>

Dig Dis Sci (Digestive diseases and sciences)
[2021, :]

Cited: 0 times

View full text PDF listing >>



An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials.

Ahmed Almradi, Christopher Ma, Geert R D'Haens, William J Sandborn, Claire E Parker, Leonardo Guizzetti, Paula Borralho Nunes, Gert De Hertogh, Roger M Feakins, Reena Khanna, Gregory Y Lauwers, Aart Mookhoek, Reetesh K Pai, Laurent Peyrin-Biroulet, Robert Riddell, Christophe Rosty, David F Schaeffer, Mark A Valasek, Siddharth Singh, Eileen Crowley, Brian G Feagan, Vipul Jairath, Rish K Pai,

<h4>Background</h4>Targeting histological remission or response in Crohn's disease (CD) is not recommended in clinical practice guidelines or as an outcome in clinical trials due to uncertainties regarding index validity and prognostic relevance.<h4>Aims</h4>To conduct a modified RAND/University of California Los Angeles appropriateness process with the goal of producing a framework to ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 53(7):784-793]

Cited: 0 times

View full text PDF listing >>



Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor.

Niels Vande Casteele, Maria T Abreu, Sarah Flier, Konstantinos Papamichael, Florian Rieder, Mark S Silverberg, Reena Khanna, Lauren Okada, Lei Yang, Anjali Jain, Adam S Cheifetz,

Therapeutic drug monitoring (TDM) with measurement of serum drug and antidrug antibodies (ADAb) is used widely to confirm therapeutic exposure, rule out immunogenicity, and optimize treatment of biologics in patients with inflammatory bowel diseases.<sup>1</sup> A recent genome-wide association study found the variant HLA-DQA1∗05 to increase the risk of development of ... Read more >>

Clin Gastroenterol Hepatol (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Safety of Biologic Therapy in Octogenarians and Nonagenarians With Inflammatory Bowel Disease in Ontario: A Case Series.

Abdul Ayoub, Vipul Jairath, Saleh Aldraiweesh, Reena Khanna, Jamie Gregor, Nilesh Chande,

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2020, 26(12):e157-e158]

Cited: 0 times

View full text PDF listing >>



Comparative Efficacy Trials in Inflammatory Bowel Disease.

Reena Khanna, G Y Zhou, Waqqas Afif,

Gastroenterology (Gastroenterology)
[2020, 159(3):1182-1184]

Cited: 0 times

View full text PDF listing >>



Pharmacokinetics of Tumor Necrosis Factor Antagonists.

Reena Khanna, Jeff McCurdy, Waqqas Afif,

Gastroenterology (Gastroenterology)
[2020, 159(1):391-393]

Cited: 0 times

View full text PDF listing >>



Adalimumab for maintenance of remission in Crohn's disease.

Cassandra M Townsend, Tran M Nguyen, Jeremy Cepek, Mohamad Abbass, Claire E Parker, John K MacDonald, Reena Khanna, Vipul Jairath, Brian G Feagan,

<h4>Background</h4>Conventional medications for Crohn's disease (CD) include anti-inflammatory drugs, immunosuppressants and corticosteroids. If an individual does not respond, or loses response to first-line treatments, then biologic therapies such as tumour necrosis factor-alpha (TNF-α) antagonists such as adalimumab are considered for treating CD. Maintenance of remission of CD is a clinically ... Read more >>

Cochrane Database Syst Rev (The Cochrane database of systematic reviews)
[2020, 5:CD012877]

Cited: 0 times

View full text PDF listing >>



Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors.

Keira A Fieldhouse, Samantha Ukaibe, Erika L Crowley, Reena Khanna, Ashley O'Toole, Melinda J Gooderham,

Background:Interleukin 17 (IL-17) inhibitors provide an excellent treatment option for patients with psoriasis and psoriatic arthritis, resulting in high levels of efficacy for skin clearance and joint improvement. Safety has also been established in clinical trials for this group of biologic agents; however, rare case reports of exacerbation or induction ... Read more >>

Drugs Context (Drugs in context)
[2020, 9:]

Cited: 4 times

View full text PDF listing >>



Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease.

Saleh Al Draiweesh, Christopher Ma, Maan Alkhattabi, Cassandra McDonald, Tran M Nguyen, Melanie Beaton, Nilesh Chande, Patrick Colquhoun, Brian G Feagan, James C Gregor, Reena Khanna, Paul Marotta, Terry Ponich, Douglas Quan, Karim Qumosani, Amindeep Sandhu, Michael Sey, Anton Skaro, Anouar Teriaky, Aze Wilson, Brian Yan, Mayur Brahmania, Vipul Jairath,

<h4>Background</h4>Patients with inflammatory bowel disease (IBD) post-liver transplant (LT) may have bowel inflammation requiring biologic therapy. We aimed to evaluate the safety of combination biologic and antirejection therapy in IBD patients after LT from a tertiary center case series and an updated literature review.<h4>Methods</h4>Inflammatory bowel disease patients undergoing LT between ... Read more >>

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2020, 26(6):949-959]

Cited: 0 times

View full text PDF listing >>



Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis.

Parambir S Dulai, Vipul Jairath, Reena Khanna, Christopher Ma, Kelly P McCarrier, Mona L Martin, Claire E Parker, Joan Morris, Brian G Feagan, William J Sandborn,

<h4>Background</h4>Patient-reported outcome (PRO) measures historically used in inflammatory bowel disease have been considered inadequate to support future drug labelling claims by regulatory agencies.<h4>Aims</h4>To develop PRO tools for use in Crohn's disease (CD) and ulcerative colitis (UC) following guidance issued by the US FDA and the ISPOR (International Society for Pharmacoeconomics ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2020, 51(11):1047-1066]

Cited: 1 time

View full text PDF listing >>



Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?

Robert Battat, Parambir S Dulai, Christopher Ma, Vipul Jairath, Brian G Feagan, William J Sandborn, Reena Khanna,

Note: This statement is mandatory. Please provide. ... Read more >>

Curr Treat Options Gastroenterol (Current treatment options in gastroenterology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.

Sarah C Davies, Isra M Hussein, Tran M Nguyen, Claire E Parker, Reena Khanna, Vipul Jairath,

<h4>Background</h4>Tofacitinib is an oral Janus kinase (JAK) inhibitor which blocks cytokine signaling involved in the pathogenesis of autoimmune diseases including ulcerative colitis (UC). The etiology of UC is poorly understood, however research suggests the development and progression of the disease is due to a dysregulated immune response leading to inflammation ... Read more >>

Cochrane Database Syst Rev (The Cochrane database of systematic reviews)
[2020, 1:CD012381]

Cited: 2 times

View full text PDF listing >>



Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.

Sarah C Davies, Tran M Nguyen, Claire E Parker, John K MacDonald, Vipul Jairath, Reena Khanna,

<b>Background: </b>Ustekinumab and briakinumab are monoclonal antibodies that target the standard p40 subunit of cytokines interleukin-12 and interleukin-23 (IL-12/23p40), which are involved in the pathogenesis of Crohn's disease (CD). A significant proportion of people with Crohn's disease fail conventional therapy or therapy with biologics (e.g. infliximab) or develop significant adverse ... Read more >>

Cochrane Database Syst Rev (The Cochrane database of systematic reviews)
[2019, 12:CD012804]

Cited: 2 times

View full text PDF listing >>



Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016).

Christopher Ma, Matthew K Smith, Leonardo Guizzetti, Remo Panaccione, Gilaad G Kaplan, Kerri L Novak, Cathy Lu, Reena Khanna, Brian G Feagan, Siddharth Singh, Vipul Jairath, Ashwin N Ananthakrishnan,

<h4>Background & aims</h4>Patients with inflammatory bowel diseases (IBDs) require repeated health care encounters, although the focus of care differs when patients are seen in ambulatory, emergency department (ED), or inpatient settings. We examined contemporary trends and disparities in IBD-related health care visits.<h4>Methods</h4>We used data from the National Ambulatory Medical Care ... Read more >>

Clin Gastroenterol Hepatol (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association)
[2020, 18(11):2500-2509.e1]

Cited: 3 times

View full text PDF listing >>



Advertisement


Disclaimer

1.5704 s